Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Gina Mazzariello Sells 15,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider directly owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Amylyx Pharmaceuticals Stock Down 2.0%

AMLX stock opened at $17.41 on Tuesday. The company has a market capitalization of $1.94 billion, a P/E ratio of -11.61 and a beta of -0.20. The company has a 50-day simple moving average of $15.34 and a 200 day simple moving average of $14.82. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $7.48 and a fifty-two week high of $19.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. Mizuho upped their target price on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.25.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently modified their holdings of the stock. First Light Asset Management LLC acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter worth $45,606,000. Maven Securities LTD purchased a new stake in shares of Amylyx Pharmaceuticals during the third quarter valued at $951,000. Commodore Capital LP acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $55,386,000. Ally Bridge Group NY LLC acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $5,944,000. Finally, Vanguard Group Inc. increased its stake in Amylyx Pharmaceuticals by 10.1% in the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after purchasing an additional 531,162 shares in the last quarter. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.